33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15823)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7078)
  4. Hematologic Malignancies, Division of (6211)
  5. Center for Hematologic Malignancies (6018)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4873)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15823)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7078)
  4. Hematologic Malignancies, Division of (6211)
  5. Center for Hematologic Malignancies (6018)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC)
    Meeting Abstract

    Makker, V.; Taylor, M. H.; Aghajanian, C.; Oaknin, A.; Mier, J.; Cohn, A. L.; Romeo, M.; Bratos, R.; Brose, M. S.; DiSimone, C.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • PD-L1 positive esophagogastric (EG) cancer is associated with distinct bacteria
    Meeting Abstract

    Maron, S. B.; Vanderbilt, C.; Sabwa, S.; Bowman, A.; Chatila, W. K.; Tang, L. H.; Strong, V. E.; Molena, D.; Jones, D. R.; Coit, D. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Update of the phase 1/2 EVOLVE study (NCT03430011)
    Meeting Abstract

    Mailankody, S.; Jakubowiak, A. J.; Htut, M.; Costa, L. J.; Lee, K.; Ganguly, S.; Kaufman, J. L.; Siegel, D. S. D.; Bensinger, W.; Cota, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Effects of electroacupuncture and auricular acupuncture for chronic pain in cancer survivors: The PEACE randomized controlled trial
    Meeting Abstract

    Mao, J. J.; Liou, K.; Panageas, K.; Baser, R. E.; Romero, S. A. D.; Li, Q. S.; Xiao, H.; Bao, T.; Kantoff, P. W.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings
    Meeting Abstract

    Lyou, Y.; Grivas, P.; Rosenberg, J. E.; Hoffman-Censits, J. H.; Quinn, D. I.; Petrylak, D. P.; Galsky, M. D.; Vaishampayan, U. N.; De Giorgi, U.; Gupta, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or Ill estrogen receptor-positive HER2-negative breast cancer (ER+HER2-BC) in postmenopausal (PM) women: Alliance A011106
    Meeting Abstract

    Ma, C. X.; Suman, V. J.; Leitch, A. M.; Sanati, S.; Vij, K. R.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O. M.; Guenther, J. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Performance of cell-free tumor DNA testing for 101 clinical laboratories on College of American Pathologists proficiency tests
    Meeting Abstract

    Lockwood, C. M.; Souers, R. J.; Vasalos, P.; Kalicanin, T.; Devereaux, K.; Graham, R. P.; Hameed, M.; Routbort, M.; Tsai, J. M.; Merker, J. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Luo, J.; Bandlamudi, C.; Ricciuti, B.; Vokes, N.; Schoenfeld, A. J.; Egger, J. V.; Sauter, J. L.; Plodkowski, A. J.; Preeshagul, I. R.; Kris, M. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer
    Meeting Abstract

    Liu, J. F.; Brady, M. F.; Matulonis, U. A.; Miller, A.; Kohn, E. C.; Swisher, E. M.; Tew, W. P.; Cloven, N. G.; Muller, C.; Bender, D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC)
    Meeting Abstract

    Liu, M. C.; Hillman, D. W.; Frith, A. E.; Lyss, A. P.; Weckstein, D. J.; Moreno-Aspitia, A.; Le-Lindqwister, N.; Isaacs, C.; Wender, D. B.; Lewis, D. A.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save